Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer
Inês Gomes(University of Lisbon), Sandra Casimiro(University of Lisbon), Guilherme Vilhais(University of Lisbon), Sara Carolina Henriques(University of Lisbon), Pedro M. Félix(University of Lisbon), Patrícia Corredeira(University of Lisbon), Luís Costa(University of Lisbon), Sara Dâmaso(Hospital de Santa Maria), André Mansinho(Hospital de Santa Maria), Inês Correia(University of Lisbon), Bernardo P. de Almeida(Research Institute of Molecular Pathology), Raquel Cruz-Duarte(University of Lisbon), Patrícia Alves(University of Lisbon), Nuno L. Barbosa‐Morais(University of Lisbon)
Cited by 27
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Nucleotide Transformer: building and evaluating robust foundation models for human genomics
|Nature Methods|2024|368
DeepSTARR predicts enhancer activity from DNA sequence and enables the de novo design of synthetic enhancers
|Nature Genetics|2022|296
The Nucleotide Transformer: Building and Evaluating Robust Foundation Models for Human Genomics
|bioRxiv (Cold Spring Harbor Laboratory)|2023|196